Open Nav

MaxCyte, Inc.

  • Douglas Doerfler, MaxCyte, Inc.

MXCT is developing its non-viral next-generation mRNA CAR-based CARMA therapeutic for solid tumors

  • Date:Wednesday, October 17
  • Time:9:00 AM - 9:15 AM
  • Room:Elizabethan C
  • Location:2nd Floor
  • Session Type:Company Presentation
  • Presentation Type:Publicly Traded Company
  • Company Description/Mission Statement:MaxCyte is a global cell-based medicines and life sciences company applying its patented cell engineering technology to help patients with high unmet medical needs in a broad range of conditions. MaxCyte is developing novel CARMA therapies for its own pipeline. CARMA™ is MaxCyte’s mRNA-based proprietary platform for autologous cell therapy. In addition, through its core business, the Company leverages its Flow Electroporation® Technology to enable its partners across the biopharmaceutical industry to advance the development of innovative medicines, particularly in cell therapy, including gene editing and immuno-oncology. The Company has placed its cutting-edge flow electroporation instruments worldwide, including with 9 of the top 10 global biopharma companies, and has 55+ partnered program licenses in cell therapy including more than 25 licensed for clinical use. With its robust delivery technology, MaxCyte helps its partners to unlock the full potential of their products.
  • Company
  • Company HQ City:Gaithersburg
  • Company HQ Country:United States
  • Company HQ State:Maryland                  
  • Ticker:MXCT; MXCR
  • Exchange:LSE Aim Market
  • CEO/Top Company Official:Douglas A. Doerfler
  • Year Founded:1998
  • Main Therapeutic Focus:Gene/Cell Therapy
  • Lead Product in Development :MCY-M11
  • Development Phase of Primary Product:Pre-Clinical
Douglas Doerfler
MaxCyte, Inc.